Technology
Health
Biotechnology

Aldeyra Therapeutics

$9.59
9
8
7
6
5
4
3
2
1
0
-
$
,
.
9
8
7
6
5
4
3
2
1
0
-
$
,
.
9
8
7
6
5
4
3
2
1
0
-
$
,
.
9
8
7
6
5
4
3
2
1
0
-
$
,
.
9
8
7
6
5
4
3
2
1
0
-
$
,
.
9
8
7
6
5
4
3
2
1
0
-
$
,
.

+$2.57 (35.99%) Today
-$0.12 (-1.24%) After Hours

Why Robinhood?

You can buy or sell ALDX and other stocks, options, ETFs, and crypto commission-free!

About

Aldeyra Therapeutics, Inc. operates as a biotechnology company. It primarily focuses on the development of new products for immune-mediated, inflammatory, orphan and other diseases that are thought to be caused in part by naturally occurring toxic chemical species known as free aldehydes. Read More The company was founded by Thomas A. Jordan and John E. Dowling on August 13, 2004 and is headquartered in Lexington, MA.

Employees
19
Headquarters
Lexington, Massachusetts
Founded
2004
Market Cap
187.39M
Price-Earnings Ratio
Dividend Yield
0.00
Average Volume
300.17K
High Today
$12.79
Low Today
$9.35
Open Price
$12.20
Volume
8.61M
52 Week High
$16.70
52 Week Low
$6.75

Collections

Technology
Health
Biotechnology
Therapy
2014 IPO
US
North America

News

Simply Wall St13h

Can You Imagine How Aldeyra Therapeutics’s (NASDAQ:ALDX) Shareholders Feel About The 68% Share Price Increase?

Aldeyra Therapeutics, Inc. (NASDAQ:ALDX) shareholders might be concerned after seeing the share price drop 14% in the last week. But that shouldn’t obscure the pleasing returns achieved by shareholders over the last three years. In fact, the company’s share price bested the return of its market index in that time, posting a gain of 68%. Check out our latest analysis for Aldeyra Therapeutics With zero revenue generated over twelve months, we don’t think that Aldeyra Therapeutics has proved its business pla...

260
Benzinga13h

Aldeyra's Eye Inflammation Drug Aces Late-Stage Trial, Stock Rises 60% (NASDAQ:ALDX)

Aldeyra Therapeutics Inc (NASDAQ: ALDX) shares are advancing strongly Tuesday following the release of the results of a late-stage study of its drug candidate for allergic conjunctivitis.

61
MarketWatch14h

Alderya Therapeutics stock soars after conjunctivitis treatment trial meets key endpoints

Shares of Aldeyra Therapeutics Inc. ALDX, -4.16% shot up 56% toward a 5-month high in premarket trade Tuesday, a day after closing at a 7-month low, after a phase 3 trial of the biotechnology company's allergic conjunctivitis treatment met its primary and secondary endpoints. Trading volume topped 440,000 shares, already more than the full-day average of about 310,000 shares. Aldeyra said it plans to meet with regulatory authorities in the second half of 2019 to discuss the results and remaining clinical re...

368

Earnings

-$0.52
-$0.45
-$0.39
-$0.32
Q2 2017
Q3 2017
Q4 2017
Q1 2018
Q2 2018
Q3 2018
Q4 2018
Q1 2019
Estimated
Actual
Expected May 14, Pre-Market
All investments involve risk and the past performance of a security, or financial product does not guarantee future results or returns. Securities offered through Robinhood Financial LLC, member FINRA/SIPC. To learn more about the information provided on this page, please see our Web Disclosures.